Article Details

Merck-Eisai's endometrial cancer therapy combo fails first-line treatment trial | Reuters

Retrieved on: 2023-12-08 17:44:13

Tags for this article:

Click the tags to see associated articles and topics

Merck-Eisai's endometrial cancer therapy combo fails first-line treatment trial | Reuters. View article details on hiswai:

Excerpt

Merck's Keytruda belongs to a class of medicines called PD-1 inhibitors that work by increasing the ability of the body's immune system to detect and ...

Article found on: www.reuters.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up